The Drug-Induced Respiratory Disease Website

Crizotinib

Pneumonitis (ILD)

Or 'ILD'. (Fr: PnP subaiguë). A.k.a. pulmonary infiltrates. Generally bilateral and symmetrical. Gradual onset. Consistent with but not specific for an NSIP-c pattern on pathology. Less- dense, severe, acute and diffuse than pattern Ia. Lacks the features of ARDS that may accompany pattern Ia. Can be in the form of disseminated linear, reticulonodular, miliary or patchy opacities. BAL is indicated to separate this pattern from PIE (Ic) or DAH (IIIa). Acute chest pain can be at the forefront. A search for microorganisms including Pneumocystis (stains, PCR) is indicated. On pathology (although not many cases undergo a confirmatory lung biopsy), there is interstitial inflammation and a more or less dense cellular interstitial cellular infiltrate (NSIP-c). Fibrosis, alveolar edema and/or a reactive epithelium denote those cases resulting from with antineoplastic chemotherapy agents. The frontier between patterns Ia and I b can be difficult to draw, so please check drugs under both Ia and Ib. Patients may quickly shift from pattern Ib to Ia particularly if the the causal drug is inappropriately continued. Prompt withdrawal must be considered, underlying disease permitting, and can be therapeutic.

Publications

Nishiyama Y, Omori S, Matsumoto H, Komiya K, Hiramatsu K

Lung Injury Induced by Crizotinib and Entrectinib in a Patient with ROS1-rearranged Non-small-cell Lung Cancer: A Case Report.

Internal medicine (Tokyo, Japan) 2023 Apr 14;; — 2023 Apr 14

Tereso A, Carreto L, Baptista M, Almeida MA

Interstitial Lung Disease Induced by Crizotinib in Non-Small-Cell Lung Cancer.

Acta medica portuguesa 2019 Mar 29;32;236-239 — 2019 Mar 29 — 236-239

Gemma A, Kusumoto M, Kurihara Y, Masuda N, Banno S, Endo Y, Houzawa H, Ueno N, Ohki E, Yoshimura A

Interstitial Lung Disease Onset and Its Risk Factors in Japanese Patients With ALK-Positive NSCLC After Treatment With Crizotinib.

Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer 2019 04;14;672-682 — 2019 04 — 672-682

Blackhall F, Ross Camidge D, Shaw AT, Soria JC, Solomon BJ, Mok T, Hirsh V, Jänne PA, Shi Y, Yang PC, Pas T, Hida T, Carpeño JC, Lanzalone S, Polli A, Iyer S, Reisman A, Wilner KD, Kim DW

Final results of the large-scale multinational trial PROFILE 1005: efficacy and safety of crizotinib in previously treated patients with advanced/metastatic ALK-positive non-small-cell lung cancer.

ESMO open 2017;2;e000219 — 2017 — e000219

Yoneda KY, Scranton JR, Cadogan MA, Tassell V, Nadanaciva S, Wilner KD, Stollenwerk NS

Interstitial Lung Disease Associated With Crizotinib in Patients With Advanced Non-Small Cell Lung Cancer: Independent Review of Four PROFILE Trials.

Clinical lung cancer 2017 09;18;472-479 — 2017 09 — 472-479

Créquit P, Wislez M, Fleury Feith J, Rozensztajn N, Jabot L, Friard S, Lavole A, Gounant V, Fillon J, Antoine M, Cadranel J

Crizotinib Associated with Ground-Glass Opacity Predominant Pattern Interstitial Lung Disease: A Retrospective Observational Cohort Study with a Systematic Literature Review.

Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer 2015 Aug;10;1148-55 — 2015 Aug — 1148-55

Maka VV, Krishnaswamy UM, Anil Kumar N, Chitrapur R, Kilara N

Acute interstitial lung disease in a patient with anaplastic lymphoma kinase-positive non-small-cell lung cancer after crizotinib therapy.

Oxford medical case reports 2014 Apr;2014;11-2 — 2014 Apr — 11-2

Asai N, Yamaguchi E, Kubo A

Successful crizotinib rechallenge after crizotinib-induced interstitial lung disease in patients with advanced non-small-cell lung cancer.

Clinical lung cancer 2014 May;15;e33-5 — 2014 May — e33-5

Rothenstein JM, Letarte N

Managing treatment-related adverse events associated with Alk inhibitors.

Current oncology (Toronto, Ont.) 2014 Feb;21;19-26 — 2014 Feb — 19-26

Watanabe N, Nakahara Y, Taniguchi H, Kimura T, Kondoh Y, Kataoka K, Sakamoto K

Crizotinib-induced acute interstitial lung disease in a patient with EML4-ALK positive non-small cell lung cancer and chronic interstitial pneumonia.

Acta oncologica (Stockholm, Sweden) 2014 Jan;53;158-60 — 2014 Jan — 158-60

Shaw AT, Kim DW, Nakagawa K, Seto T, Crinó L, Ahn MJ, De Pas T, Besse B, Solomon BJ, Blackhall F, Wu YL, Thomas M, O'Byrne KJ, Moro-Sibilot D, Camidge DR, Mok T, Hirsh V, Riely GJ, Iyer S, Tassell V, Polli A, Wilner KD, Jänne PA

Crizotinib versus chemotherapy in advanced ALK-positive lung cancer.

The New England journal of medicine 2013 Jun 20;368;2385-94 — 2013 Jun 20 — 2385-94

Jett JR, Carr LL

Targeted therapy for non-small cell lung cancer.

American journal of respiratory and critical care medicine 2013 Oct 15;188;907-12 — 2013 Oct 15 — 907-12

Timm A, Kolesar JM

Crizotinib for the treatment of non-small-cell lung cancer.

American journal of health-system pharmacy : AJHP : official journal of the American Society of Health-System Pharmacists 2013 Jun 01;70;943-7 — 2013 Jun 01 — 943-7

Ou SH

Crizotinib: a novel and first-in-class multitargeted tyrosine kinase inhibitor for the treatment of anaplastic lymphoma kinase rearranged non-small cell lung cancer and beyond.

Drug design, development and therapy 2011;5;471-85 — 2011 — 471-85

Kwak EL, Bang YJ, Camidge DR, Shaw AT, Solomon B, Maki RG, Ou SH, Dezube BJ, Jänne PA, Costa DB, Varella-Garcia M, Kim WH, Lynch TJ, Fidias P, Stubbs H, Engelman JA, Sequist LV, Tan W, Gandhi L, Mino-Kenudson M, Wei GC, Shreeve SM, Ratain MJ, Settleman J,

Anaplastic lymphoma kinase inhibition in non-small-cell lung cancer.

The New England journal of medicine 2010 Oct 28;363;1693-703 — 2010 Oct 28 — 1693-703

Diagnosing DIRD